Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Finished Goods (2016 - 2021)

Medifast (MED) has disclosed Finished Goods for 9 consecutive years, with $100.7 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Finished Goods rose 387.59% year-over-year to $100.7 million, compared with a TTM value of $100.7 million through Sep 2021, up 387.59%, and an annual FY2020 reading of $29.9 million, down 4.65% over the prior year.
  • Finished Goods was $100.7 million for Q3 2021 at Medifast, up from $73.1 million in the prior quarter.
  • Across five years, Finished Goods topped out at $100.7 million in Q3 2021 and bottomed at $10.5 million in Q3 2017.
  • Average Finished Goods over 5 years is $30.3 million, with a median of $27.5 million recorded in 2018.
  • The sharpest move saw Finished Goods crashed 38.84% in 2020, then surged 387.59% in 2021.
  • Year by year, Finished Goods stood at $13.4 million in 2017, then soared by 90.27% to $25.5 million in 2018, then grew by 22.76% to $31.3 million in 2019, then fell by 4.65% to $29.9 million in 2020, then soared by 237.22% to $100.7 million in 2021.
  • Business Quant data shows Finished Goods for MED at $100.7 million in Q3 2021, $73.1 million in Q2 2021, and $40.5 million in Q1 2021.